Nephrocare Health Services Share Price
622.50-4.45 (-0.71%)
+32.10% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
APOLLOHOSPNSE
MANIPALHOSNSE
MAXHEALTHNSE
ASTERDMNSE
FORTISNSE
NHNSE
MEDANTANSE
LALPATHLABNSE
KIMSNSE
AGARWALEYENSE
NEPHROPLUSNSE
Nephrocare Health Services Share Price
622.50-4.45 (-0.71%)
+32.10% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 32% | 32% |
| - | - | - | 15% |
| - | - | - | - |
| 7% | 7% | 11% | 9% |
Peer Comparison
Symbol
APOLLOHOSP
MANIPALHOS
MAXHEALTH
ASTERDM
FORTIS
NH
MEDANTA
LALPATHLAB
KIMS
AGARWALEYE
NEPHROPLUS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 7,666 | ₹113572 Cr | 54.35 | 40.39 | 207.67 | ₹1942 Cr |
| 684.05 | ₹91899 Cr | 102.99 | 1.96 | 11.95 | ₹892 Cr |
| 873.4 | ₹88192 Cr | 60.53 | 3.31 | 19.84 | ₹1442 Cr |
| 677.05 | ₹59287 Cr | 186.04 | 0.31 | 6.76 | ₹388 Cr |
| 763 | ₹58898 Cr | 56.21 | 3.53 | 20.1 | ₹1042 Cr |
| 1,695.3 | ₹35233 Cr | 43.17 | 10.14 | 65.36 | ₹806 Cr |
| 1,274 | ₹34792 Cr | 62.56 | 5.91 | 29.85 | ₹556 Cr |
| 1,897.8 | ₹32654 Cr | 60.26 | 10.11 | 42.51 | ₹505 Cr |
| 687.9 | ₹29155 Cr | 142.71 | 1.04 | 12.74 | ₹241 Cr |
| 467 | ₹15300 Cr | 103.12 | 1.43 | 13.88 | ₹133 Cr |
| 626.95 | ₹6454 Cr | 83.99 | 3.19 | 16.66 | ₹77 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|
| ₹282 Cr | ₹266 Cr | ₹260 Cr | ₹228 Cr | ₹219 Cr | ₹197 Cr |
| ₹7 Cr | ₹12 Cr | ₹3 Cr | ₹7 Cr | ₹4 Cr | ₹5 Cr |
| ₹289 Cr | ₹277 Cr | ₹263 Cr | ₹234 Cr | ₹223 Cr | ₹203 Cr |
| ₹242 Cr | ₹238 Cr | ₹221 Cr | ₹200 Cr | ₹187 Cr | ₹171 Cr |
| ₹71 Cr | ₹65 Cr | ₹64 Cr | ₹54 Cr | ₹55 Cr | ₹49 Cr |
| ₹2 Cr | ₹3 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr |
| ₹45 Cr | ₹36 Cr | ₹36 Cr | ₹29 Cr | ₹30 Cr | ₹26 Cr |
| ₹36 Cr | ₹33 Cr | ₹32 Cr | ₹24 Cr | ₹25 Cr | ₹20 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Less Impairment of Assets
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| — | — | — | — |
| ₹20 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| ₹18 Cr | ₹13 Cr | ₹6 Cr | ₹8 Cr |
| ₹1078 Cr | ₹566 Cr | ₹402 Cr | ₹375 Cr |
| ₹1078 Cr | ₹566 Cr | ₹402 Cr | ₹375 Cr |
| ₹1116 Cr | ₹584 Cr | ₹414 Cr | ₹389 Cr |
| ₹5 L | ₹96 Cr | ₹123 Cr | ₹81 Cr |
| -₹30 Cr | -₹19 Cr | -₹23 Cr | -₹17 Cr |
| ₹46 Cr | ₹26 Cr | ₹23 Cr | ₹17 Cr |
| ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr |
| ₹21 Cr | ₹108 Cr | ₹126 Cr | ₹86 Cr |
| — | — | — | — |
| ₹143 Cr | ₹113 Cr | ₹71 Cr | ₹43 Cr |
| ₹124 Cr | ₹63 Cr | ₹78 Cr | ₹38 Cr |
| ₹13 Cr | ₹101 Cr | ₹93 Cr | ₹92 Cr |
| ₹19 Cr | ₹7 Cr | ₹1 Cr | ₹1 Cr |
| ₹299 Cr | ₹284 Cr | ₹243 Cr | ₹175 Cr |
| ₹1437 Cr | ₹976 Cr | ₹782 Cr | ₹650 Cr |
| ₹23 Cr | ₹226 Cr | ₹243 Cr | ₹196 Cr |
| — | — | — | — |
| ₹841 Cr | ₹679 Cr | ₹564 Cr | ₹386 Cr |
| ₹323 Cr | ₹282 Cr | ₹208 Cr | ₹146 Cr |
| ₹1 Cr | ₹0 | ₹0 | ₹0 |
| ₹517 Cr | ₹396 Cr | ₹356 Cr | ₹239 Cr |
| ₹6 Cr | ₹6 Cr | ₹69 L | ₹32 Cr |
| ₹7 Cr | ₹0 | ₹0 | ₹0 |
| ₹7 Cr | ₹0 | ₹0 | ₹0 |
| ₹23 Cr | ₹10 Cr | ₹16 Cr | ₹10 Cr |
| ₹46 Cr | ₹18 Cr | ₹20 Cr | ₹42 Cr |
| ₹598 Cr | ₹431 Cr | ₹392 Cr | ₹325 Cr |
| — | — | — | — |
| ₹171 Cr | ₹51 Cr | ₹0 | ₹0 |
| ₹33 Cr | ₹27 Cr | ₹26 Cr | ₹26 Cr |
| ₹317 Cr | ₹266 Cr | ₹203 Cr | ₹159 Cr |
| ₹255 Cr | ₹155 Cr | ₹61 Cr | ₹14 Cr |
| ₹8 Cr | ₹6 Cr | ₹7 Cr | ₹4 Cr |
| ₹56 Cr | ₹40 Cr | ₹94 Cr | ₹121 Cr |
| ₹839 Cr | ₹545 Cr | ₹390 Cr | ₹324 Cr |
| ₹540 Cr | ₹261 Cr | ₹147 Cr | ₹150 Cr |
| ₹1437 Cr | ₹976 Cr | ₹782 Cr | ₹650 Cr |
| ₹109 | ₹3,217 | ₹2,310 | ₹2,167 |
| ₹109 | ₹643 | ₹462 | ₹433 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ₹97 Cr | ₹87 Cr | ₹33 Cr | -₹9 Cr |
| ₹168 Cr | ₹93 Cr | ₹80 Cr | ₹69 Cr |
| -₹6 Cr | -₹44 Cr | -₹33 Cr | -₹53 Cr |
| ₹260 Cr | ₹136 Cr | ₹80 Cr | ₹7 Cr |
| ₹233 Cr | ₹135 Cr | ₹72 Cr | ₹11 Cr |
| -₹410 Cr | -₹125 Cr | -₹51 Cr | -₹78 Cr |
| ₹157 Cr | ₹54 Cr | ₹27 Cr | ₹60 Cr |
| -₹21 Cr | ₹65 Cr | ₹48 Cr | -₹7 Cr |
| ₹126 Cr | ₹61 Cr | ₹14 Cr | ₹19 Cr |
| ₹19 Cr | ₹2 L | -₹1 Cr | ₹2 Cr |
| ₹124 Cr | ₹126 Cr | ₹61 Cr | ₹14 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
Nephrocare Health Services Share Price
622.50-4.45 (-0.71%)
+32.10% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 6 out of 9 oscillators
RSI
28.97Sell
STOCH %K
4.42Buy
MACD Level(12,26)
-21.90Sell
Ultimate Oscillator
36.09Sell
Aroon Oscillator
-36.00Sell
BOP
-0.48Sell
CCI
-111.04Buy
Williams %R
-95.58Buy
Momentum
-120.85Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 7 out of 9 moving averages
EMA 9
649.24Sell
SMA 9
645.48Sell
EMA 21
675.75Sell
SMA 21
697.77Sell
EMA 50
685.05Sell
SMA 50
696.20Sell
EMA 200
607.25Buy
SMA 200
607.86Buy
WMA 20
670.64Sell
Pivot
Pivot
Classic
Resistance 5
738.77
Resistance 4
712.02
Resistance 3
685.27
Resistance 2
658.52
Resistance 1
642.73
Pivot
631.77
Support 1
615.98
Support 2
605.02
Support 3
578.27
Support 4
551.52
Support 5
524.77
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Nephrocare Health Services Share Price
622.50-4.45 (-0.71%)
+32.10% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|
| 63.85% | 63.85% | 63.85% |
| 8.78% | 9.94% | 3.59% |
| 5.85% | 5.47% | 4.31% |
| 3.20% | 3.17% | 3.44% |
| 18.32% | 17.57% | 24.81% |
Bulk & block deals
Name
Polar Capital Funds Plc-Healthcare Opportunities Fund
Mansi Share And Stock Broking Private Limited
Edoras Investment Holdings Pte Ltd
Edoras Investment Holdings Pte Ltd
Mansi Share And Stock Broking Private Limited
Polar Capital Funds Plc-Healthcare Opportunities Fund
Poonawalla Vision Fund I
Mansi Share And Stock Broking Private Limited
Marwadi Chandarana Intermediaries Brokers Private Limited
Rajasthan Global Securities Pvt Ltd
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 24 Sep 2026 | Purchase | 179.47 Cr | ₹705 | 25.46 L | Bulk | 2.537075 | NSE |
| 24 Sep 2026 | Purchase | 58.06 Cr | ₹705.24 | 8.23 L | Bulk | 0.820515 | NSE |
| 24 Sep 2026 | Sell | 59.37 Cr | ₹705.03 | 8.42 L | Bulk | 0.83925 | NSE |
| 24 Sep 2026 | Sell | 59.80 Cr | ₹710.18 | 8.42 L | Bulk | 0.83925 | NSE |
| 24 Sep 2026 | Sell | 57.96 Cr | ₹710.45 | 8.16 L | Bulk | 0.813006 | NSE |
| 17 Dec 2025 | Purchase | 165.14 Cr | ₹481.77 | 34.28 L | Bulk | 3.416227 | NSE |
| 17 Dec 2025 | Purchase | 29.89 Cr | ₹490.05 | 6.10 L | Bulk | 0.607929 | NSE |
| 17 Dec 2025 | Purchase | 27.93 Cr | ₹490 | 5.70 L | Bulk | 0.568085 | NSE |
| 17 Dec 2025 | Purchase | 25.78 Cr | ₹482.75 | 5.34 L | Bulk | 0.532182 | NSE |
| 17 Dec 2025 | Purchase | 2.46 Cr | ₹491 | 50 K | Bulk | 0.04983 | NSE |
Insider trading & SAST
Client name
Polar Capital Funds Plc & Others
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 Jan 2026 | Other | Acquisition | 0.21 | 5.05 | 0 | — | 2.14 L | 19 Dec 2025 | Market | 50,74,256 | SAST | 29(1) | — |
Nephrocare Health Services Share Price
622.50-4.45 (-0.71%)
+32.10% past 1 Year
Nephrocare Health Services is engaged in offering comprehensive dialysis care through its network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported
Corporate Actions
Date
Type
Details
Company details
Nephrocare Health Services Share Price
622.50-4.45 (-0.71%)
+32.10% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Nephrocare Health Services Share Price
622.50-4.45 (-0.71%)
+32.10% past 1 Year
News
Nephrocare Health Services Reports Rs 409 Crore NSE Block Trade
Equity
NEPHROPLUS
Nephrocare Health Services Schedules Analyst And Investor Meeting On September 29
Equity
NEPHROPLUS
Nephrocare Health to acquire dialysis facility assets in the Philippines
Equity
NEPHROPLUS
Nephrocare Health buys full ownership of Almaty dialysis centre
Equity
NEPHROPLUS
Nephrocare Health reiterates medium term growth outlook of 15 to 20 percent
Equity
NEPHROPLUS
Nephrocare Health Services reports higher Q1 EBITDA and stable margin
Equity
NEPHROPLUS
Nephrocare Health Services reports Q1 revenue growth to Rs 280 crores
Equity
NEPHROPLUS
Nephrocare Health Services reports higher Q1 net profit year on year
Equity
NEPHROPLUS
Nephrocare Health Services sees Rs 70 crore block trade in NEPHROPLUS stock
Equity
NEPHROPLUS
Nephrocare Health Services to acquire Philippines dialysis center assets
Equity
NEPHROPLUS
Nephrocare Health trades higher on the BSE
Equity
NEPHROPLUS
Nephrocare Health shines as its arm inks asset transfer pact with Amica Healthcare System Corporation
Equity
NEPHROPLUS
Nephrocare Health’s arm inks asset transfer pact with Amica Healthcare System Corporation
Equity
NEPHROPLUS
Nephrocare Health arm acquires Philippines dialysis assets to expand global footprint
Equity
NEPHROPLUS
Nephrocare Health jumps as its arm inks asset transfer pact with Inocentes Dialysis Clinic
Equity
NEPHROPLUS
Nephrocare Health’s arm inks asset transfer pact with Inocentes Dialysis Clinic
Equity
NEPHROPLUS
Nephrocare Health Services unit signs asset transfer deal with Inocentes Dialysis Clinic
Equity
NEPHROPLUS
Nephrocare Health Services rises as its arm incorporates wholly-owned subsidiary in Kazakhstan
Equity
NEPHROPLUS
Nephrocare Health Services’ arm incorporates wholly-owned subsidiary in Kazakhstan
Equity
NEPHROPLUS
Nephrocare Health Se - Quaterly Results
Equity
NEPHROPLUS